CureVac Statistics
Total Valuation
CureVac has a market cap or net worth of $546.27 million. The enterprise value is $92.60 million.
| Market Cap | 546.27M |
| Enterprise Value | 92.60M |
Important Dates
The next estimated earnings date is Tuesday, May 28, 2024, before market open.
| Earnings Date | May 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CureVac has 223.88 million shares outstanding. The number of shares has increased by 19.43% in one year.
| Shares Outstanding | 223.88M |
| Shares Change (YoY) | +19.43% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 45.43% |
| Owned by Institutions (%) | 23.80% |
| Float | 118.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 9.17 |
| PS Ratio | 11.98 |
| Forward PS | 6.52 |
| PB Ratio | 0.85 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.56, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.56 |
| Quick Ratio | 3.17 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.57 |
Financial Efficiency
Return on equity (ROE) is -48.40% and return on invested capital (ROIC) is -47.75%.
| Return on Equity (ROE) | -48.40% |
| Return on Assets (ROA) | -33.80% |
| Return on Capital (ROIC) | -47.75% |
| Revenue Per Employee | $50,461 |
| Profits Per Employee | -$355,745 |
| Employee Count | 904 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 9.67 |
Taxes
In the past 12 months, CureVac has paid $71,439 in taxes.
| Income Tax | 71,439 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.76% in the last 52 weeks. The beta is 2.51, so CureVac's price volatility has been higher than the market average.
| Beta (1Y) | 2.51 |
| 52-Week Price Change | -69.76% |
| 50-Day Moving Average | 3.17 |
| 200-Day Moving Average | 5.67 |
| Relative Strength Index (RSI) | 24.42 |
| Average Volume (30 Days) | 783,872 |
Short Selling Information
The latest short interest is 5.01 million, so 2.24% of the outstanding shares have been sold short.
| Short Interest | 5.01M |
| Short Previous Month | 4.86M |
| Short % of Shares Out | 2.24% |
| Short % of Float | 4.23% |
| Short Ratio (days to cover) | 6.80 |
Income Statement
In the last 12 months, CureVac had revenue of $45.62 million and -$321.59 million in losses. Loss per share was -$1.57.
| Revenue | 45.62M |
| Gross Profit | -115.04M |
| Operating Income | -328.09M |
| Pretax Income | -322.25M |
| Net Income | -321.59M |
| EBITDA | -295.34M |
| EBIT | -314.31M |
| Loss Per Share | -$1.57 |
Balance Sheet
The company has $498.58 million in cash and $44.90 million in debt, giving a net cash position of $453.67 million or $2.03 per share.
| Cash & Cash Equivalents | 498.58M |
| Total Debt | 44.90M |
| Net Cash | 453.67M |
| Net Cash Per Share | $2.03 |
| Equity / Book Value | 642.17M |
| Book Value Per Share | 2.87 |
| Working Capital | 411.74M |
Cash Flow
In the last 12 months, operating cash flow was -$291.48 million and capital expenditures -$62.99 million, giving a free cash flow of -$354.47 million.
| Operating Cash Flow | -291.48M |
| Capital Expenditures | -62.99M |
| Free Cash Flow | -354.47M |
| FCF Per Share | -$1.58 |
Margins
Gross margin is -252.18%, with operating and profit margins of -719.22% and -704.99%.
| Gross Margin | -252.18% |
| Operating Margin | -719.22% |
| Pretax Margin | -706.43% |
| Profit Margin | -704.99% |
| EBITDA Margin | -647.44% |
| EBIT Margin | -689.02% |
| FCF Margin | -777.06% |
Dividends & Yields
CureVac does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.43% |
| Shareholder Yield | -19.43% |
| Earnings Yield | -58.87% |
| FCF Yield | -64.89% |
Analyst Forecast
The average price target for CureVac is $15.00, which is 514.75% higher than the current price. The consensus rating is "Hold".
| Price Target | $15.00 |
| Price Target Difference | 514.75% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 30.94% |
| EPS Growth Forecast (5Y) | -42.39% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CureVac has an Altman Z-Score of -1.73 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.73 |
| Piotroski F-Score | 2 |